Rekombinanter Varicella Zoster Virus gE (VZV gE) Antikörper

Produktnummer ABIN7482309

Produktdetails

Target: Varicella Zoster Virus gE (VZV gE)

Antikörpertyp: Recombinant Antibody

Reaktivität: Varicella Zoster Virus (VZV)

Wirt: Human

Klonalität: Monoklonal

Konjugat: Unkonjugiert

Applikation: ELISA

Verwendungszweck: Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (1B10) (MALS verified)

Güteklasse: MALS verified

Klon: 1B10

Isotyp: IgG1

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Lagerung: -20 °C

Antigendetails

Target: Varicella Zoster Virus gE (VZV gE)

Andere Bezeichnung: VZV gE

Substanzklasse: Viral Protein

Hintergrund: Varicella-zoster virus (VZV) is a neurotropic virus belonging to the Herpesviridae family. Primary VZV infection causes chickenpox and is followed by a life-long latent infection established mainly in the cranial and dorsal root ganglia. Reactivation of the virus is often associated with shingles (herpes zoster). Glycoprotein E (gE) is one of the known glycoproteins (gB, gC, gE, gH, gI, gK, gI) of VZV that is most abundantly expressed on the surface of virus and infected cells, playing an important role in viral replication and cell-to-cell spread. The strongly immunogenic gE can provide strong IgG signal in body fluid, which makes it ideal to be developed as an antigen for analysis of IgG antibodies. gE also demonstrates high potency as a vaccine immunogen and is formulated as the single viral envelope protein that constitutes the GSK VZV recombinant subunit vaccine Shingrix®.The antibody can reacte with gE specially.